New Anticoagulant Agents: Direct Thrombin Inhibitors

Cardiology Clinics

Volumn 26, Issue 2, 2008, Pages 169-187

  Nutescu, Edith A ^a   Shapiro, Nancy L ^a   Chevalier, Aimee ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ARGATROBAN; CLOPIDOGREL; CYTOCHROME P450; DABIGATRAN; DABIGATRAN ETEXILATE; DALTEPARIN; DESULFATOHIRUDIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HEPARIN COFACTOR II; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; PLACEBO; STREPTOKINASE; THIENOPYRIDINE DERIVATIVE; THROMBIN; THROMBIN INHIBITOR; THROMBOCYTE FACTOR 4; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTINUOUS INFUSION; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HEPATITIS; HUMAN; IMMUNE SYSTEM; INFUSION RATE; INTERNATIONAL NORMALIZED RATIO; ISCHEMIA; JAUNDICE; KIDNEY FAILURE; KNEE SURGERY; LIVER FAILURE; LIVER FUNCTION; LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; LUNG EMBOLISM; MORTALITY; ORTHOPEDIC SURGERY; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROPHYLAXIS; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; STROKE; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOSIS; TOTAL HIP PROSTHESIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNITED STATES; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; FIBRINOLYTIC AGENTS; HALF-LIFE; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; PIPECOLIC ACIDS; PYRIDINES; RECOMBINANT PROTEINS; STROKE; THROMBIN;

EID: 41949084883     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2007.12.005     Document Type: Review

References (86)

1. Bates S.M., and Weitz J.L. The mechanism of action of thrombin inhibitors. J Invasive Cardiol 12 Suppl F (2000) 27-32
2. Nutescu E.A., and Wittkowsky A.K. Direct thrombin inhibitors for anticoagulation. Ann Pharmacother 38 (2004) 99-109
3. Weitz J.I., Hirsh J., and Samama M.M. New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 265-286
4. Nutescu E.A., Shapiro N.L., Chevalier A., et al. A pharmacologic overview of current and emerging anticoagulants. Cleve Clin J Med 72 Suppl 1 (2005) S2-S6
5. Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet 359 (2002) 294-302
6. Berlex Laboratories. Product information: refludan (Lepirudin) rDNA. Available at:. www.refludan.com Accessed July 5, 2005
7. Greinacher A., Volpel H., Janssens U., et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 99 (1999) 73-80
8. Greinacher A., Janssens U., Berg G., et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation 100 (1999) 587-593
9. Lubenow N., Eichler P., Lietz T., et al., HIT Investigators Group. Lepirudin in patients with heparin-induced thrombocytopenia-results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 3 (2005) 2428-2436
10. Tardy B., Lecompte T., Boelhen F., et al. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood 108 (2006) 1492-1496
11. McDaniel M., and Soff G. Decreasing adverse drug events associated with lepirudin and argatroban for the treatment of heparin-induced thrombocytopenia. [abstract]. Blood 104 (2004) 495
12. Hacquard M., Maistre E., and Lecompte T. Lepirudin: is the approved dosing schedule too high?. J Thromb Haemost 3 (2005) 2593-2596
13. Kiser T.H., Jung R., Maclaren R., et al. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparininduced thrombocytopenia. Pharmacotherapy 25 (2005) 1736-1745
14. Schiele F., Lindgaerde F., Eriksson H., et al. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. International Multicentre Hirudin Study Group. Thromb Haemost 77 (1997) 834-838
15. Frenkel E.P., Shen Y.M., and Haley B.B. The direct thrombin inhibitors: their role and use for rational anticoagulation. Hematol Oncol Clin North Am 19 (2005) 119-145
16. Dager W.E., Dougherty J.A., and Nguyen P.H. Heparin-induced thrombocytopenia: Treatment options and special considerations. Pharmacotherapy 27 4 (2007) 564-587
17. Eriksson B.I., Ekman S., Lindbratt S., et al. Prevention of thromboembolism with use of recombinant hirudin: results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am 79 (1997) 326-333
18. Erikkson B.I., Wille-Jorgensen P., Kalebo P., et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 337 (1997) 1329-1335
19. Serruys P.W., Herrman J.P., Simon R., et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. The Helvetica Investigators. N Engl J Med 333 (1995) 757-763
20. The GUSTO-IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO)-IIb Investigators. N Engl J Med 335 (1996) 775-782
21. Warkentin T.E. Bivalent direct thrombin inhibitors: hirudin and bivalirudin. Best Pract Res Clin Haematol 17 (2004) 105-125
22. Monreal M., Costa J., and Salva P. Pharmacological properties of hirudin and its derivatives. Drug Ther (NY) 8 (1996) 171-182
23. The Medicines Company. Product information: angiomax (Bivalirudin). Available at:. www.angiomax.com Accessed July 5, 2005
24. Lui H.K. Dosage, pharmacological effects and clinical outcomes for bivalirudin in percutaneous coronary intervention. J Invasive Cardiol 12 Suppl F (2000) 41-52
25. Bittl J.A., Chaitman B.R., Feit F., et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 142 (2001) 952-959
26. Lincoff A.M., Kleiman N.S., Kottke-Marchant K., et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 143 (2002) 847-853
27. Lincoff A.M., Bittl J.A., Kleiman N.S., et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention. The Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-1 Trial. Am J Cardiol 93 (2004) 1092-1096
28. Lincoff A.M., Bittl J.A., Harrington R.A., et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. REPLACE-2 randomized trial. JAMA 289 (2003) 853-863
29. Chew D.P., Lincoff A.M., Gurm H., et al. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention: a subanalysis of the REPLACE-2 trial. Am J Cardiol 95 (2005) 581-585
30. Lincoff A.M., Kleiman N.S., Kereiakes D.J., et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization. REPLACE-2 randomized trial. JAMA 292 (2004) 696-703
31. Cohen D.J., Lincoff A.M., Lavelle T.A., et al. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol 44 (2004) 1792-1800
32. Stone G.W., McLaurin B.T., Cox D.A., et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355 (2006) 2203-2216
33. Stone G.W., Ware J.H., Bertrand M.E., et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA 298 21 (2007) 2497-2506
34. White H. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 358 (2001) 1855-1863
35. Mahaffey K.W., Lewis B.E., Wildermann N.M., et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol 15 (2003) 611-616
36. Francis J.L., Drexler A., Gwyn G., et al. Successful use of bivalirudin in the treatment of patients suspected, or at risk for, heparin-induced thrombocytopenia. Blood 104 (2004) 4077
37. Koster A., Dyke C.M., Aldea G., et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 83 (2007) 572-577
38. Mann M.J., Tseng E., Ratcliffe M., et al. Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia. J Heart Lung Transplant 24 (2005) 222-225
39. Clayton S.B., Ascell J.R., Crumbley A.J., et al. Cardiopulmonary bypass with bivalirudin in type II heparin-induced thrombocytopenia. Ann Thorac Surg 78 (2004) 2167-2169
40. Gordon G., Rastegar H., Schumann R., et al. Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. J Cardiothorac Vasc Anesth 17 (2003) 632-635
41. Glaxo Smith Kline. Product information: argatroban. Available at:. www.argatroban.com Accessed July 5, 2005
42. LaMonte M.P., Brown P.M., and Hursting M.J. Alternative parenteral anticoagulation with argatroban, a direct thrombin inhibitor. Expert Rev Cardiovasc Ther 3 (2005) 31-41
43. Gray A., Wallis D.E., Hurstin M.J., et al. Argatroban therapy for heparin-induced thrombocytopenia in acutely ill patients. Clin Appl Thromb Hemost 13 (2007) 353-361
44. Lewis B.E., Wallis D.E., Leya F., et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 163 (2003) 1849-1856
45. Lewis B.E., Wallis D.E., Berkowitz S.D., et al., ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103 (2001) 1838-1843
46. Beinderlinden M., Treschan T.A., Gorlinger K., et al. Argatroban anticoagulation in critically ill patients. Ann Pharmacother 41 (2007) 749-754
47. Nutescu E.A., and Bauman J.L. Shifting paradigms in oral anticoagulation management. J Cardiovasc Pharmacol Ther 3 (2004) 149-150
48. Ansell J., Hirsh J., Poller L., et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 204S-233S
49. Nutescu E.A., Helgason C.M., Briller J., et al. New blood thinner offers first potential alternative in 50 years: ximelagatran. J Cardiovasc Nurs 19 (2004) 374-383
50. Eriksson U.G., Bredberg U., Hoffman K.J., et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos 31 (2003) 294-305
51. Eriksson U.G., Bredberg U., Gislen K., et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 59 (2003) 35-43
52. Wolzt M., Wollbratt M., Svensson M., et al. Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. Eur J Clin Pharmacol 59 (2003) 537-543
53. Gustafsson D., and Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res 109 (2003) S9-S15
54. Wahlander K., Eriksson-Lepkowska M., Frison L., et al. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 42 (2003) 755-764
55. Sarich T.C., Teng R., Peters G.R., et al. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran. Clin Pharmacokinet 42 (2003) 485-492
56. Eriksson U.G., Johansson S., Attman P.O., et al. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. Clin Pharmacokinet 42 (2003) 743-753
57. Johansson L.C., Frison L., Logren U., et al. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 42 (2003) 381-392
58. Johansson L.C., Andersson M., Fager G., et al. No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. Clin Pharmacokinet 42 (2003) 475-484
59. Elg M., Gustafsson D., and Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res 94 (1999) 187-197
60. Bredberg E., Andersson T.B., Frison L., et al. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clin Pharmacokinet 42 (2003) 765-777
61. Schutzer K.M., Wall U., Lonnerstedt C., et al. Bioequivalence of ximelagatran, an oral direct thrombin inhibitor, as whole or crushed tablets or dissolved formulation. Curr Med Res Opin 20 (2004) 325-331
62. Sarich T.C., Johansson S., Schutzer K.M., et al. The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol. J Clin Pharmacol 44 (2004) 388-393
63. Eriksson B.I., Bergqvist D., Kalebo P., et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomized trial. Lancet 360 (2002) 1441-1447
64. Eriksson B.I., Agnelli G., Cohen A.T., et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaprin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO III study. Thromb Haemost 89 (2003) 288-296
65. Eriksson B.I., Agnelli G., Cohen A.T., et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 1 (2003) 2490-2496
66. Colwell C.W., Berkowitz S.D., Davidson B.L., et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement: a randomized, double-blind study. J Thromb Haemost 1 (2003) 2119-2130
67. Francis C.W., Berkowitz S.D., Comp P.C., et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 349 (2003) 1703-1712
68. Colwell C.W., Berkowitz S.D., Comp P.C., et al. Randomized, double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR). Blood 102 11 part 1 (2003) 14a
69. Francis C.W., Davidson B.L., Berkowitz S.D., et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blinded trial. Ann Intern Med 137 (2002) 648-655
70. Buller H.R., Agnelli G., Hull R.D., et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 401S-428S
71. Fiessinger J.N., Huisman M.V., Davidson B.L., et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis. JAMA 293 (2005) 681-689
72. Schulman S., Wahlander K., Lundstrom T., et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 349 (2003) 1713-1721
73. Singer D.E., Albers G.W., Dalen J.E., et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 429S-456S
74. Halperin J.L. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 146 (2003) 431-438
75. Olsson S.B. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet 362 (2003) 1691-1698
76. SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. JAMA 293 (2005) 690-698
77. Samsa G.P., Matchar D.B., Goldstein L.B., et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med 160 (2000) 967-973
78. He R. Integrated executive summary for FDA review for NDA 21-686 Exanta (ximelagatran). Food and Drug Administration. Available at:. http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4069B1_03_FDA-Backg rounder-Execsummaryredacted.pdf Accessed July 5, 2005
79. Zimmerman H.J. Drug-induce liver disease. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver (1978), Appleton-Century-Crofts, New York
80. Stangier J., Erikkson B.I., Dahl O.E., et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 45 (2005) 555-563
81. Erikkson B.I., Dahl O.E., Ahnfelt L., et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2 (2004) 1573-1580
82. Erikkson B.I., Dahl O.E., Buller H.R., et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 3 (2005) 103-111
83. Dahl O.E., Rosencher N., Kurth A.A., et al. RE-NOVATE Study Group. Dabigatran etexilate vs. enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370 9591 (2007) 949-956
84. Friedman RJ, Caprini JA, Comp PC et al. Dabigatran etexilate versus enoxaparin in preventing venous thromboembolism following total knee arthroplasty. Abstract presented at Congress of the International Society on Thrombosis and Haemostasis in Geneva, Switzerland, July 2007.
85. Eriksson B.I., Dahl O.E., Rosencher N., et al. RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5 11 (2007) 2178-2185
86. Caprini JA, Hwang E, Hantel S et al. The oral direct thrombin inhibitor dabigatran etexilate is effective and safe for prevention of major venous thromboembolism following orthopaedic surgery. Abstract presented at Congress of the International Society on Thrombosis and Haemostasis in Geneva, Switzerland, July 2007.